A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

Karen Kelly; N. Mikhaeel-Kamel; Z. Pan; J. Murphy; S. Prindiville; Jr Bunn P.A.

A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

Karen Kelly, N. Mikhaeel-Kamel, Z. Pan, J. Murphy, S. Prindiville, Jr Bunn P.A.

Research output: Contribution to journal › Article › peer-review

Abstract

Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

Original language	English (US)
Pages (from-to)	3474-3479
Number of pages	6
Journal	Clinical Cancer Research
Volume	6
Issue number	9
State	Published - 2000
Externally published	Yes

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this

@article{09ef3a652d0144dba4658e591fb90645,

title = "A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer",

abstract = "Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.",

author = "Karen Kelly and N. Mikhaeel-Kamel and Z. Pan and J. Murphy and S. Prindiville and {Bunn P.A.}, Jr",

year = "2000",

language = "English (US)",

volume = "6",

pages = "3474--3479",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "9",

}

TY - JOUR

T1 - A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

AU - Kelly, Karen

AU - Mikhaeel-Kamel, N.

AU - Pan, Z.

AU - Murphy, J.

AU - Prindiville, S.

AU - Bunn P.A., Jr

PY - 2000

Y1 - 2000

N2 - Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

AB - Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0033817994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033817994&partnerID=8YFLogxK

M3 - Article

C2 - 10999731

AN - SCOPUS:0033817994

VL - 6

SP - 3474

EP - 3479

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -

A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

Abstract

ASJC Scopus subject areas

Other files and links

Cite this